UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Oncogenic BRAF(V600E) Promotes Stromal Cell-Mediated Immunosuppression Via Induction of Interleukin-1 in Melanoma

Clinical cancer research, 2012-10, Vol.18 (19), p.5329-5340

2012

Volltextzugriff (PDF)

Single-cell profiling of dynamic cytokine secretion and the phenotype of immune cells

PloS one, 2017-08, Vol.12 (8), p.e0181904

2017

Volltextzugriff (PDF)

COVID‐19: a pandemic experience that illuminates potential reforms to health research

EMBO molecular medicine, 2020-11, Vol.12 (11), p.e13278-n/a

2020

Volltextzugriff (PDF)

Targeting the cancer mutanome of breast cancer

Nature medicine, 2018-06, Vol.24 (6), p.703-704

Radvanyi, Laszlo G.

2018

Volltextzugriff (PDF)

Tumor-Infiltrating Lymphocyte Therapy: Addressing Prevailing Questions

The cancer journal (Sudbury, Mass.), 2015-11, Vol.21 (6), p.450-464

Radvanyi, Laszlo G

2015

Volltextzugriff (PDF)

Randomized phase II trial of lymphodepletion plus adoptive cell transfer of tumor-infiltrating lymphocytes, with or without dendritic cell vaccination, in patients with metastatic melanoma

Journal for immunotherapy of cancer, 2021-05, Vol.9 (5), p.e002449

2021

Volltextzugriff (PDF)

Improving Antitumor Immune Responses by Circumventing Immunoregulatory Cells and Mechanisms

Clinical cancer research, 2006-08, Vol.12 (16), p.4794-4803

2006

Volltextzugriff (PDF)

New insights on the role of CD8+CD57+ T-cells in cancer

Oncoimmunology, 2012-09, Vol.1 (6), p.954-956

2012

Volltextzugriff (PDF)

Inhibition of the B7-H3 immune checkpoint limits tumor growth by enhancing cytotoxic lymphocyte function

Cell research, 2017-08, Vol.27 (8), p.1034-1045

2017

Volltextzugriff (PDF)

BRAF Inhibition Increases Tumor Infiltration by T cells and Enhances the Antitumor Activity of Adoptive Immunotherapy in Mice

Clinical cancer research, 2013-01, Vol.19 (2), p.393-403

2013

Volltextzugriff (PDF)

Adoptive T-cell therapy using autologous tumor-infiltrating lymphocytes for metastatic melanoma: current status and future outlook

The cancer journal (Sudbury, Mass.), 2012-03, Vol.18 (2), p.160-175

2012

Volltextzugriff (PDF)

Multifaceted Role of BTLA in the Control of CD8 + T-cell Fate after Antigen Encounter

Clinical cancer research, 2017-10, Vol.23 (20), p.6151-6164

2017

Volltextzugriff (PDF)

Advances in the Treatment of Metastatic Melanoma: Adoptive T-Cell Therapy

Seminars in oncology, 2012-04, Vol.39 (2), p.215-226

2012

Volltextzugriff (PDF)

BRAF(V600) Inhibitor GSK2118436 Targeted Inhibition of Mutant BRAF in Cancer Patients Does Not Impair Overall Immune Competency

Clinical cancer research, 2012-04, Vol.18 (8), p.2326-2335

2012

Volltextzugriff (PDF)

Advances in the development of cancer immunotherapies

Trends in immunology, 2013-02, Vol.34 (2), p.90-98

2013

Volltextzugriff (PDF)

Immunosuppression in Melanoma Immunotherapy: Potential Opportunities for Intervention

Clinical cancer research, 2006-04, Vol.12 (7), p.2359s-2365s

2006

Volltextzugriff (PDF)

PD-1 and BTLA and CD8+ T-cell "exhaustion" in cancer: "Exercising" an alternative viewpoint

Oncoimmunology, 2012-08, Vol.1 (5), p.735-738

2012

Volltextzugriff (PDF)

Costimulation through the CD137/4-1BB pathway protects human melanoma tumor-infiltrating lymphocytes from activation-induced cell death and enhances antitumor effector function

Journal of immunotherapy (1997), 2011-04, Vol.34 (3), p.236-250

2011

Volltextzugriff (PDF)

Peptide-Based Vaccination and Induction of CD8+ T-Cell Responses Against Tumor Antigens in Breast Cancer

BioDrugs : clinical immunotherapeutics, biopharmaceuticals, and gene therapy, 2015-02, Vol.29 (1), p.15-30

2015

Volltextzugriff (PDF)

Utilizing T-cell Activation Signals 1, 2, and 3 for Tumor-infiltrating Lymphocytes (TIL) Expansion: The Advantage Over the Sole Use of Interleukin-2 in Cutaneous and Uveal Melanoma

Journal of immunotherapy (1997), 2018-11, Vol.41 (9), p.399-405

2018

Volltextzugriff (PDF)

4-1BB-Enhanced Expansion of CD8 + TIL from Triple-Negative Breast Cancer Unveils Mutation-Specific CD8 + T Cells

Cancer immunology research, 2017-06, Vol.5 (6), p.439-445

2017

Volltextzugriff (PDF)

Activation and propagation of tumor-infiltrating lymphocytes on clinical-grade designer artificial antigen-presenting cells for adoptive immunotherapy of melanoma

Journal of immunotherapy (1997), 2014-11, Vol.37 (9), p.448-460

2014

Volltextzugriff (PDF)

BTLA marks a less-differentiated tumor-infiltrating lymphocyte subset in melanoma with enhanced survival properties

Oncoimmunology, 2015-08, Vol.4 (8), p.e1014246-e1014246

2015

Volltextzugriff (PDF)

Defective STAT1 activation associated with impaired IFN-γ production in NK and T lymphocytes from metastatic melanoma patients treated with IL-2

Oncotarget, 2016-06, Vol.7 (24), p.36074-36091

2016

Volltextzugriff (PDF)

1 – 25 von 89

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(83)
Mit Volltextzugriff
(76)

Publikationsform

Sprache

Englisch
(87)
Ungarisch
(2)

Erscheinungsjahr

n.n

Thema

Science & Technology
(65)
Life Sciences & Biomedicine
(59)
Humans
(49)
Oncology
(38)
Immunology
(29)
Animals
(25)
Female
(21)
Immunotherapy
(21)
Melanoma
(20)
Cancer
(17)
Male
(17)
Biological And Medical Sciences
(16)
Mice
(16)
Melanoma - Immunology
(15)
Medical Sciences
(14)
Melanoma - Therapy
(12)
Middle Aged
(11)
Tumor-Infiltrating Lymphocytes
(11)
Tumors
(11)
Cd8-Positive T-Lymphocytes - Immunology
(10)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Oncogenic BRAF(V600E) Promotes Stromal Cell-Mediated Immunosuppression Via Induction of Interleukin-1 in Melanoma

Single-cell profiling of dynamic cytokine secretion and the phenotype of immune cells

COVID‐19: a pandemic experience that illuminates potential reforms to health research

Targeting the cancer mutanome of breast cancer

Tumor-Infiltrating Lymphocyte Therapy: Addressing Prevailing Questions

Randomized phase II trial of lymphodepletion plus adoptive cell transfer of tumor-infiltrating lymphocytes, with or without dendritic cell vaccination, in patients with metastatic melanoma

Improving Antitumor Immune Responses by Circumventing Immunoregulatory Cells and Mechanisms

New insights on the role of CD8+CD57+ T-cells in cancer

Inhibition of the B7-H3 immune checkpoint limits tumor growth by enhancing cytotoxic lymphocyte function

BRAF Inhibition Increases Tumor Infiltration by T cells and Enhances the Antitumor Activity of Adoptive Immunotherapy in Mice

Adoptive T-cell therapy using autologous tumor-infiltrating lymphocytes for metastatic melanoma: current status and future outlook

Multifaceted Role of BTLA in the Control of CD8 + T-cell Fate after Antigen Encounter

Advances in the Treatment of Metastatic Melanoma: Adoptive T-Cell Therapy

BRAF(V600) Inhibitor GSK2118436 Targeted Inhibition of Mutant BRAF in Cancer Patients Does Not Impair Overall Immune Competency

Advances in the development of cancer immunotherapies

Novel algorithmic approach predicts tumor mutation load and correlates with immunotherapy clinical outcomes using a defined gene mutation set

Immunosuppression in Melanoma Immunotherapy: Potential Opportunities for Intervention

PD-1 and BTLA and CD8+ T-cell "exhaustion" in cancer: "Exercising" an alternative viewpoint

Costimulation through the CD137/4-1BB pathway protects human melanoma tumor-infiltrating lymphocytes from activation-induced cell death and enhances antitumor effector function

Peptide-Based Vaccination and Induction of CD8+ T-Cell Responses Against Tumor Antigens in Breast Cancer

Utilizing T-cell Activation Signals 1, 2, and 3 for Tumor-infiltrating Lymphocytes (TIL) Expansion: The Advantage Over the Sole Use of Interleukin-2 in Cutaneous and Uveal Melanoma

4-1BB-Enhanced Expansion of CD8 + TIL from Triple-Negative Breast Cancer Unveils Mutation-Specific CD8 + T Cells

Activation and propagation of tumor-infiltrating lymphocytes on clinical-grade designer artificial antigen-presenting cells for adoptive immunotherapy of melanoma

BTLA marks a less-differentiated tumor-infiltrating lymphocyte subset in melanoma with enhanced survival properties

Defective STAT1 activation associated with impaired IFN-γ production in NK and T lymphocytes from metastatic melanoma patients treated with IL-2

Suchergebnisse filtern